Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Research Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS) on Bullrun: market cap CNY 30.84B, P/E 34.5, dividend yield 12.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker600329.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCNY
- Market capCNY 30.84B
- P/E34.5
- Dividend yield12.0%
- Financial periodQ2 2026
- RevenueCNY 939.39M
- Net incomeCNY 220.94M
- Free cash flowCNY 390.91M
- Gross margin73.3%
Valuation Snapshot
latest market cap is CNY 30.84B; P/E is 34.5; dividend yield is 12.0%.
Peer valuation comparison
Latest P/E is 34.53x versus a Healthcare sector median of 21.8x (58.4% above).
Latest dividend yield is 11.96% versus a Healthcare sector median of 2.4% (398.3% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 30.84B | 34.5 | 11.7% | 4.79 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 4.79 CNY, yield 12.0%.
About Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs.
ETFs that hold Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
US-listed ETFs
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is held by 14 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
| JPMorgan Betabuilders Emerging Markets Equity ETF (BBEM) | 0.01% | 0.15% |
Portfolios as filed with the SEC on Form N-PORT, dated July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's market cap?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's market capitalization is CNY 30.84B.
What is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's P/E ratio?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's price-to-earnings (P/E) ratio is 34.5.
Does Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited pay a dividend?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has a dividend yield of 12.0%.
What does Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited do?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs.